<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01592474</url>
  </required_header>
  <id_info>
    <org_study_id>SET</org_study_id>
    <nct_id>NCT01592474</nct_id>
  </id_info>
  <brief_title>Evaluation of Brain Atrophy in CIS Patients on Avonex</brief_title>
  <official_title>Evolution of Gray Matter Atrophy Over 4 Years in Observational Study of Early IFNβ-1a I.M. Treatment in High Risk Subjects After Clinically Isolated Syndrome (SET Substudy)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jacobs Neurological Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charles University, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University at Buffalo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is&#xD;
&#xD;
        -  To examine if Avaonex can delay the development of clinically definite multiple&#xD;
           sclerosis.&#xD;
&#xD;
        -  To investigate if Avonex can delay disability progression by slowing brain atrophy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Multiple sclerosis (MS) is a chronic inflammatory disorder characterized by focal areas&#xD;
           of demyelination in the central nervous system (CNS). MRI findings suggest that we&#xD;
           should look at gray matter atrophy as a marker of the disease process in MS.&#xD;
&#xD;
        -  Avonex is a proven effective disease-modifying treatment, which reduces total brain and&#xD;
           GM atrophy and should be considered first-line therapy in patients with RRMS and CIS.&#xD;
&#xD;
        -  The original SET study is an open-label observational study of high risk subjects after&#xD;
           CIS for development of CDMS that will enroll 220 patients who have started Avonex&#xD;
           immediately after their first clinical attack in Czech Republic, and are followed with&#xD;
           clinical and MRI examinations for 4 years at 0, 6, 12, 24, 36 and 48 months. The&#xD;
           clinical and MRI acquisition examinations of this study are conducted in Czech Republic.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Can Avonex delay development of clinically definite MS?</measure>
    <time_frame>5</time_frame>
    <description>To examine whether Avonex can delay the development of clinically definite multiple sclerosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Can Avonex delay disability progression?</measure>
    <time_frame>5</time_frame>
    <description>To investigate if Avonex can delay disability progression by slowing brain atrophy</description>
  </secondary_outcome>
  <enrollment type="Actual">180</enrollment>
  <condition>Multiple Sclerosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Multiple sclerosis patients being treated with Avonex after first clinical attack.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  MRI findings must reveal at least 2 hyperintense lesions on T2-WI or FLAIR images at&#xD;
             first clinical onset&#xD;
&#xD;
          -  CSF examination should confirm oligoclonal bands (examination must be done in an&#xD;
             internationally approved lab and the CSF taken before the treatment of attack starts)&#xD;
&#xD;
          -  Age 18 - 55 years&#xD;
&#xD;
          -  Effective contraception in female patients of childbearing potential&#xD;
&#xD;
          -  Kurtzke EDSS ≤ 3.5 at baseline&#xD;
&#xD;
          -  Willingness to accept the plan of the study and compliance with the study&#xD;
&#xD;
          -  Time from the beginning of first symptoms of CIS to baseline visit should not exceed 4&#xD;
             months (baseline MRI and baseline visit will be organized first 28 days after last&#xD;
             steroid administration)&#xD;
&#xD;
          -  CIS attack is treated by at least 3g of methylprednisolone without taper&#xD;
&#xD;
          -  In case of severe attack 1 g of cyclophosphamide does not disqualify the patient from&#xD;
             the study if first MRI and CSF examination was done before treatment administered&#xD;
&#xD;
          -  No active major organ disease especially of hepatic or thyroid origin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The clinical diagnosis of MS is definite (the second attack occurs before the baseline&#xD;
             visit)&#xD;
&#xD;
          -  Age less than 18 or more than 55&#xD;
&#xD;
          -  Non-effective contraception method or pregnancy planning&#xD;
&#xD;
          -  Active major organ disease, especially hepatic or endocrinologic&#xD;
&#xD;
          -  Cooperation of the subject cannot be ensured&#xD;
&#xD;
          -  Kurtzke EDSS higher than 3.5 at baseline&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Zivadinov, MD,PhD,FAAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>University at Buffalo</affiliation>
  </overall_official>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>May 3, 2012</study_first_submitted>
  <study_first_submitted_qc>May 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2012</study_first_posted>
  <last_update_submitted>July 8, 2014</last_update_submitted>
  <last_update_submitted_qc>July 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University at Buffalo</investigator_affiliation>
    <investigator_full_name>Robert Zivadinov, MD, PhD</investigator_full_name>
    <investigator_title>Director, Buffalo Neuroimaging Analysis Center, Professor</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Avonex</keyword>
  <keyword>Brain atrophy</keyword>
  <keyword>MRI</keyword>
  <keyword>Interferon-beta 1a</keyword>
  <keyword>IFN Beta 1-a</keyword>
  <keyword>Clinically isolated syndrome</keyword>
  <keyword>CIS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

